



Copaxone[®] (glatiramer) – First-time generic

- On October 3, 2017, [Mylan launched](#) an AP-rated generic version of Teva's [Copaxone \(glatiramer\)](#) 40 mg/mL injection.
 - Mylan also launched generic Copaxone 20 mg/mL injection.
- Copaxone is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS).
- Copaxone 20 mg/mL injection is also generically available as [Glatopa[®]](#), Sandoz's [AP-rated](#) product approved in April 2015.
- Mylan is introducing Mylan MS Advocate[™], a comprehensive patient support service program to help patients get started on and stay on track with their physician's treatment plan for Mylan's glatiramer injection. The program includes an interactive mobile app, in-home injection training, a 24/7 patient support center, co-pay assistance for eligible patients and ongoing support from an MS-experienced nurse.
- According to QuintilesIMS, Copaxone 40 mg/mL injection had U.S. sales of \$3.64 billion for the 12 months ending July 31, 2017.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.